Loading…
Based on limited metadata, this FDA Warning Letter issued to Coupler Enterprises on September 15, 2020, concerns drug manufacturing or distribution operations. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The warning falls under FDA's drug product jurisdiction, though the specific issuing office is not identified in this metadata. Additional documentation would be needed to identify the particular compliance concerns that prompted the agency's enforcement action.